Your English writing platform
Discover LudwigSuggestions(5)
Exact(5)
Recent studies have demonstrated that, in advanced colorectal carcinoma (CRC) patients, extended RAS (in KRAS exons 2 4 and NRAS exons 2 4) and BRAF mutations are negative predictors for anti-EGFR treatment efficacy and negative prognostic factor, respectively.
K-Ras mutations are negative predictor of clinical outcomes in colorectal cancer patients undergoing anti-EGFR therapies [35].
Several studies suggest that K- RAS mutations are negative predictive factors of response to single-agent TKI treatment in advanced/metastatic NSCLC (Zhu et al, 2008).
For example, it has been shown that epidermal growth factor receptor (EGFR) as well as k-ras mutations are negative predictive factors for treatment response, and BRAF mutations are negative predictive factors for survival in patients with colorectal cancer[ 45 48].
Acknowledge most mutations are negative as opposed to positive.
Similar(55)
Cytogenetic analysis was normal and tests for the JAK2 and BCR/ABL mutations were negative.
At this time, DNA analysis for the HLBX9 gene mutations was negative.
Bone marrow aspiration biopsy was compatible with idiopathic erythrocytosis as JAK-2 V617F and Exon 12 mutations were negative.
Likewise, the IHC tests for the detection of exon 19 deletions and exon 21 missense mutations were negative in all the 47 cases.
While 20 and 31 hypervirulent PHI-base mutations were negative regulators of cell-to-cell communication and the establishment of biofilms or growth patterns which are tightly coordinated with the host, respectively.
A group of 39 patients aged under 36 years and for whom the search for Brca1 gene mutations was negative, and a group of 36 cases of sporadic cancers without data on their Brca status were used as controls.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com